heart attack

Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
Diabetes increases risk of heart attack by halfUK study: Diabetes increases risk of heart attack death. Here are the surprising details.
FDA denies claims for Zetia, VytorinFDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
FDA expands Brilinta approval for long-term use in patients with heart attack historyFDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.
Diabetes drug may reduce stroke, CV deathsJardiance is the first diabetes drug that has also been shown to lower strokes, heart attacks and cardiovascular deaths, according to a new study.
FDA warns of early MI, stroke risk with non-aspirin NSAIDsMI and stroke risk can rise just weeks after NSAID use commences. Labels will be updated to reflect this.
5 things to know about cholesterol-lowering PCSK9 inhibitorsThis summer, the first two drugs in the new class of cholesterol-lowering medications, known as PCSK9 inhibitors, are expected to be approved by the FDA. If approved, PCSK9 inhibitors will change how chronic conditions are treated.
Heartburn drugs linked to heart attacksCertain Protein-pump inhibitors (PPIs) such as omeprazole (Prilosec) are associated with a short-term risk of heart attacks and other cardiac events, according to a new study.
FDA grants priority review to expand use of BrilintaThe FDA has granted Priority Review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack.
Grassroots FDA partnership aims to reduce heart disease deathsFDA has joined nonprofit National Forum for Heart Disease and Stroke Prevention to advance the cause of a heart-healthy and stroke-free society in a first-of-its-kind cooperative public education program to reduce the burdens of heart disease and stroke.